What we do
Heart disease is still the leading cause of death worldwide, making it the most significant health threat. Every year, more than 20 million people die because of cardiovascular diseases.
Cardiovascular CRO Expert
Optimapharm, for over 17 years, has been driving advancements in cardiovascular disease treatment through successful clinical trials and collaborative partnerships. We have established collaborative relationships with highly experienced sites, most of which are part of large university centres with thousands of daily outpatients; thanks to their proven recruitment we can expedite your cardiovascular study.
Successfully completing over 75 cardiovascular clinical trials phases I-IV and complex medical devices, with an enrolment of more than 7 000 patients, we help shape new clinical evidences that have the potential to support new treatments and therapies for cardiovascular diseases.
Additionally, more than 200 highly educated Optimapharm team members have conducted cardiovascular clinical studies in 20+ different indications.
You can rely on Optimapharm to achieve your recruitment targets and ensure a successful delivery of your next cardiovascular studies.
75+ Studies conducted
46% of Phase II and Phase III
7 000+
patients enrolled
Close collaboration with
490+ sites
28 different indications
Optimapharm’s top 5 indications in Cardiovascular studies
Staff experience
211 staff members with Cardiovascular projects experience
Case study
Case study
Cardiovascular Factsheet
Brochure
